Presentation
Uveal melanoma has a very poor prognosis with high medical need and orphan disease status. After treatment for the eye tumor, 30% of patients develop neovascular glaucoma leading to enucleation and more than 30% of patients develop lethal metastatic uveal melanoma within just one year, due to lack of effective therapy. Roca Therapeutics’ mission is to develop personalized treatments based on new small molecules against metastatic uveal melanoma and associated ocular complications.
Contact
contact@roca-therapeutics.com
Address
Nice, Provence-Alpes-Côte d’Azur
Website
https://www.linkedin.com/company/roca-therapeutics
Targeting innovation : All